Shots:

• Part A of a P-I/II trial evaluates the safety & tolerability of MRx-4DP0004 vs PBO in addition to ICS with/out LABA in a ratio (1:1) in 34 patients with asthma while ~90 patients will enroll in Part B & assess the clinical efficacy, exploratory immune & microbiome biomarkers
• The trial meet its 1EPs i.e., patients experienced AE (61.1% vs 75.0%) with no SAEs, reductions in ACQ-6 score (83.3% vs 56.3%) & asthma exacerbation (5.6% vs 12.5%), reduction from baseline in ACQ-6 score (50.0% vs 37.5%)
• Additionally, patients reduced the use of SABA (50% vs 18.8%), increase in AQLQ scores (50.0% vs 31.3%). MRx-4DP0004 is an oral, immunomodulatory, single strain LBPs & is being developed for asthma

Ref: Businesswire | Image: PharmiWeb